BR112014004784A2 - polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo - Google Patents
polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeoInfo
- Publication number
- BR112014004784A2 BR112014004784A2 BR112014004784A BR112014004784A BR112014004784A2 BR 112014004784 A2 BR112014004784 A2 BR 112014004784A2 BR 112014004784 A BR112014004784 A BR 112014004784A BR 112014004784 A BR112014004784 A BR 112014004784A BR 112014004784 A2 BR112014004784 A2 BR 112014004784A2
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptide
- composition containing
- drug composition
- glycosylated
- glycosylated polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011192202 | 2011-09-04 | ||
| PCT/JP2012/072380 WO2013032011A1 (ja) | 2011-09-04 | 2012-09-03 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014004784A2 true BR112014004784A2 (pt) | 2017-03-21 |
Family
ID=47756483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014004784A BR112014004784A2 (pt) | 2011-09-04 | 2012-09-03 | polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9422357B2 (pt) |
| EP (1) | EP2752424B1 (pt) |
| JP (1) | JP6178238B2 (pt) |
| KR (1) | KR102031998B1 (pt) |
| CN (2) | CN103930441B (pt) |
| AU (1) | AU2012302636B2 (pt) |
| BR (1) | BR112014004784A2 (pt) |
| CA (1) | CA2847334C (pt) |
| DK (1) | DK2752424T3 (pt) |
| IN (1) | IN2014CN02399A (pt) |
| RU (1) | RU2624034C2 (pt) |
| SG (2) | SG10201601324VA (pt) |
| TW (1) | TWI662966B (pt) |
| WO (1) | WO2013032011A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102031998B1 (ko) * | 2011-09-04 | 2019-10-14 | 가부시키가이샤 도우사 고가쿠 겐큐쇼 | 당쇄 부가 폴리펩티드 및 당해 폴리펩티드를 포함하는 의약 조성물 |
| CN106146649B (zh) | 2011-09-04 | 2020-09-01 | 株式会社糖锁工学研究所 | 附加糖链的多肽和含有该多肽的医药组合物 |
| CN111855827B (zh) * | 2019-04-24 | 2022-09-16 | 岛津企业管理（中国）有限公司 | 多糖蛋白结合疫苗中多糖蛋白结合位点结合率的测定方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4000259A (en) * | 1975-06-16 | 1976-12-28 | American Home Products Corporation | Cyclic dodecapeptide analogs of somatostatin and intermediates |
| US4380953A (en) | 1978-09-11 | 1983-04-26 | Filper Corporation | Transfer mechanism in a peach pitter |
| US4310518A (en) | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4235886A (en) | 1979-10-31 | 1980-11-25 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4280953A (en) * | 1979-11-08 | 1981-07-28 | The Salk Institute For Biological Studies | Glycosylated analogs of somatostatin |
| US4316891A (en) * | 1980-06-14 | 1982-02-23 | The Salk Institute For Biological Studies | Extended N-terminal somatostatin |
| LU85269A1 (fr) | 1984-03-26 | 1985-10-14 | Techland S A | Composes nouveaux de somatostatine,procede pour leur synthese,preparation a usage veterinaire contenant lesdits composes et procede pour le traitement d'animaux |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| NL194729C (nl) | 1986-10-13 | 2003-01-07 | Novartis Ag | Werkwijze voor de bereiding van peptidealcoholen via vaste fase. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| DK0843725T3 (da) * | 1995-08-11 | 2002-08-12 | Novozymes As | Fremgangmåde til fremstilling af polypeptidvarianter |
| US5750499A (en) | 1995-10-18 | 1998-05-12 | The Salk Institute For Biological Studies | Receptor-selective somatostatin analogs |
| FI965181A (fi) | 1996-12-20 | 1998-06-21 | Map Medical Technologies Oy | Polyalkoholi-peptidijohdannaiset |
| JP3385947B2 (ja) | 1998-01-05 | 2003-03-10 | 松下電器産業株式会社 | バルクフィーダ |
| WO2001004287A1 (en) * | 1999-07-07 | 2001-01-18 | Maxygen Aps | A method for preparing modified polypeptides |
| US20030036181A1 (en) * | 2000-06-30 | 2003-02-20 | Okkels Jens Sigurd | Peptide extended glycosylated polypeptides |
| AU2002254691B8 (en) * | 2001-04-23 | 2008-02-14 | Mallinckrodt Inc. | Tc and Re labeler radioactive glycosylated octreotide derivatives |
| DK1405858T3 (da) | 2001-06-19 | 2013-02-18 | Glytech Inc | Fremgangsmåde til at fremstille sukkerkædeasparaginderivat. |
| US7943763B2 (en) | 2002-07-05 | 2011-05-17 | Otsuka Chemical Holdings Co., Ltd. | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides |
| TWI335920B (en) | 2002-12-24 | 2011-01-11 | Yasuhiro Kajihara | Sugar chain asparagine derivatives, sugar chain asparagine and sugar chain and manufacture thereof |
| CN100413889C (zh) * | 2002-12-24 | 2008-08-27 | 大塚化学株式会社 | 糖链天冬酰胺衍生物、糖链天冬酰胺和糖链以及它们的制造方法 |
| US7273934B2 (en) | 2002-12-26 | 2007-09-25 | Otsuka Chemical Co., Ltd. | Three-branched sugar-chain asparagine derivatives, the sugar-chain asparagines, the sugar chains, and processes for producing these |
| KR20050095609A (ko) | 2003-02-04 | 2005-09-29 | 오츠카 가가쿠 가부시키가이샤 | 당사슬 아스파라긴 유도체의 제조방법 |
| WO2004101619A1 (ja) * | 2003-05-15 | 2004-11-25 | Shionogi Co., Ltd. | 機能的糖ペプチドの合理的設計および合成 |
| JP4607017B2 (ja) | 2003-07-28 | 2011-01-05 | 大塚化学株式会社 | アミノ化複合型糖鎖誘導体及びその製造方法 |
| KR100604994B1 (ko) * | 2004-01-30 | 2006-07-26 | 한국생명공학연구원 | 알파1,6-만노실트랜스퍼라제를 코딩하는 한세눌라폴리모르파 기원의 신규 유전자 및 상기 유전자가 결손된한세눌라 폴리모르파 변이주를 이용한 재조합 당단백질생산 방법 |
| TWI342880B (en) | 2005-07-19 | 2011-06-01 | Otsuka Chemical Co Ltd | Method for producing sugar chain derivatives, and sugar chain derivatives |
| US20070025910A1 (en) * | 2005-07-29 | 2007-02-01 | Norenberg Jeffrey P | Anticancer therapy |
| EP1941902A1 (en) * | 2007-01-02 | 2008-07-09 | Novartis AG | Use of Somatostatin analogs in cluster headache |
| CA2696615A1 (en) * | 2007-06-19 | 2008-12-24 | Otsuka Chemical Co., Ltd. | Oligosaccharide chain added glp-1 peptide |
| WO2009103965A1 (en) | 2008-02-19 | 2009-08-27 | Asterion Limited | Modified linkers |
| US8765669B2 (en) | 2008-06-17 | 2014-07-01 | Glytech, Inc. | Glycosylated GLP-1 peptide |
| EP2294080A2 (en) * | 2008-06-27 | 2011-03-16 | Novo Nordisk Health Care AG | N-glycosylated human growth hormone with prolonged circulatory half-life |
| CN106146649B (zh) | 2011-09-04 | 2020-09-01 | 株式会社糖锁工学研究所 | 附加糖链的多肽和含有该多肽的医药组合物 |
| KR102031998B1 (ko) * | 2011-09-04 | 2019-10-14 | 가부시키가이샤 도우사 고가쿠 겐큐쇼 | 당쇄 부가 폴리펩티드 및 당해 폴리펩티드를 포함하는 의약 조성물 |
-
2012
- 2012-09-03 KR KR1020147008130A patent/KR102031998B1/ko active IP Right Grant
- 2012-09-03 EP EP12828271.2A patent/EP2752424B1/en active Active
- 2012-09-03 RU RU2014112046A patent/RU2624034C2/ru active
- 2012-09-03 AU AU2012302636A patent/AU2012302636B2/en active Active
- 2012-09-03 SG SG10201601324VA patent/SG10201601324VA/en unknown
- 2012-09-03 US US14/342,359 patent/US9422357B2/en active Active
- 2012-09-03 CN CN201280053754.2A patent/CN103930441B/zh active Active
- 2012-09-03 WO PCT/JP2012/072380 patent/WO2013032011A1/ja active Application Filing
- 2012-09-03 JP JP2013531454A patent/JP6178238B2/ja active Active
- 2012-09-03 SG SG11201400289SA patent/SG11201400289SA/en unknown
- 2012-09-03 CA CA2847334A patent/CA2847334C/en active Active
- 2012-09-03 IN IN2399CHN2014 patent/IN2014CN02399A/en unknown
- 2012-09-03 DK DK12828271T patent/DK2752424T3/da active
- 2012-09-03 CN CN201710964257.2A patent/CN107522779B/zh active Active
- 2012-09-03 BR BR112014004784A patent/BR112014004784A2/pt not_active Application Discontinuation
- 2012-09-04 TW TW101132259A patent/TWI662966B/zh active
-
2016
- 2016-07-08 US US15/205,960 patent/US9937264B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013032011A1 (ja) | 2013-03-07 |
| TW201315478A (zh) | 2013-04-16 |
| RU2624034C2 (ru) | 2017-06-30 |
| AU2012302636B2 (en) | 2016-09-15 |
| CN103930441A (zh) | 2014-07-16 |
| JPWO2013032011A1 (ja) | 2015-03-23 |
| JP6178238B2 (ja) | 2017-08-09 |
| CN107522779A (zh) | 2017-12-29 |
| KR102031998B1 (ko) | 2019-10-14 |
| IN2014CN02399A (pt) | 2015-06-19 |
| TWI662966B (zh) | 2019-06-21 |
| CN107522779B (zh) | 2021-10-26 |
| US9937264B2 (en) | 2018-04-10 |
| US20140336116A1 (en) | 2014-11-13 |
| KR20140059829A (ko) | 2014-05-16 |
| CA2847334A1 (en) | 2013-03-07 |
| AU2012302636A1 (en) | 2014-03-20 |
| CA2847334C (en) | 2020-09-01 |
| EP2752424A1 (en) | 2014-07-09 |
| RU2014112046A (ru) | 2015-11-27 |
| US9422357B2 (en) | 2016-08-23 |
| SG10201601324VA (en) | 2016-03-30 |
| EP2752424A4 (en) | 2015-04-22 |
| US20170157260A1 (en) | 2017-06-08 |
| SG11201400289SA (en) | 2014-05-29 |
| EP2752424B1 (en) | 2019-09-11 |
| CN103930441B (zh) | 2017-11-17 |
| DK2752424T3 (da) | 2019-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014004936A2 (pt) | polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo | |
| SMT201700008B (it) | Composizione farmaceutica | |
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| CO7020851A2 (es) | Proteínas y péptidos modificados | |
| HK1200871A1 (en) | Modified dna-binding proteins and uses thereof dna- | |
| DK3181128T3 (da) | Farmaceutisk nilotinib-sammensætning | |
| DK3246018T3 (da) | Farmaceutisk sammensætning | |
| BR112013014644A2 (pt) | composição farmacêutica e complexo | |
| DK2536830T3 (da) | Polypeptider | |
| BR112014000055A2 (pt) | polipeptídeos de fusão de relaxina e usos dos mesmos | |
| BR112013017629A2 (pt) | laminina-521 recombinante | |
| BR112015004936A2 (pt) | composição farmacêutica revestida contendo regorafenib | |
| ZA201305504B (en) | Compositions containing glycosylated antibodies and uses thereof | |
| BR112015011111A2 (pt) | proteína multifuncional e formulação farmacêutica | |
| EE201300005A (et) | Ravimkoostis | |
| SMT201600097B (it) | Composizione farmaceutica liquida che comprende nitisone | |
| DK2897594T3 (da) | Farmaceutisk sammensætning | |
| PL2858490T3 (pl) | Rekombinowane elementy dna do ekspresji rekombinowanych białek w owadach | |
| SMT201500005B (it) | Composizione framaceutica inalabile | |
| FI20116212A (fi) | Polypeptidi | |
| BR112015002646A2 (pt) | composto e composição farmacêutica | |
| BR112012029461A2 (pt) | composição farmacêutica contendo solifenacina | |
| BR112014004784A2 (pt) | polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo | |
| BR112014009501A2 (pt) | organogel e com´posição cosmética | |
| SG10201602076QA (en) | Glycosylated polypeptide and pharmaceutical composition containing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/54 (2017.01), C07K 14/655 (2006.01), A61K |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |